Category: Covid-19

Page 725«..1020..724725726727..730740..»

Can we trust Chinese Covid-19 science? – The Guardian

October 12, 2020

It started badly, with gag orders, cover-ups and ignored offers of help from overseas, but then the Chinese government seized the narrative. It reined in the burgeoning epidemic of Covid-19 at home, and started exporting its rapidly accumulating scientific knowledge of the disease to the rest of the world. Chinese science has often been marginalised and even mistrusted in the west. But will the pandemic change its standing in the world?

China has moved from student to teacher, says Kate Mason, an anthropologist at Brown University in Rhode Island and author of Infectious Change, an account of how the 2002-3 epidemic of severe acute respiratory syndrome (Sars) in China transformed the way the country managed public health. After Sars, she says, western experts went to China to help it put in place an evidence-based health system that was informed by international research. That system now exists, with its most visible symbol being the Chinese Center for Disease Control and Prevention in Beijing, and this time it has been Chinese experts giving instruction abroad. It has been a good year for China, Mason says.

But China has long held a goal to lead the world in science, and it was already well on its way to achieving it before the pandemic. Five years ago, it didnt appear in the top 10 countries for university rankings; this year, its joint sixth. It is second in the world for output of science and engineering publications, behind the European Union but ahead of the United States, and the impact of Chinese research as measured by the proportion of articles that are highly cited doubled between 2000 and 2016, growing much faster than that of the US and the EU, which increased by around 10% and 30% respectively over the same period.

This turbo-charged performance reflects a long-term policy of rebuilding Chinese research and education in the post-Mao Zedong era, says political scientist and China watcher Anna Ahlers of the Max Planck Institute for the History of Science (MPIWG) in Berlin. Starting from the 1980s, the Chinese government began investing heavily in infrastructure, mass education and the training of a cadre of sophisticated researchers across all Stem disciplines. Then, 20 years ago, its focus shifted outward to achieving global prominence.

Among the initiatives that were devised in this new phase were programmes for recruiting talent from abroad, such as the Thousand Talents Plan, and, domestically, a system of incentives for scientists to publish. These bore fruit, as reflected in the rankings, but they also had negative consequences. The pressure to publish with large cash bonuses paid to scientists for papers appearing in top scientific journals resulted in an increase in academic fraud. Meanwhile, the Thousand Talents Plan has been criticised by the US, Canada and others as a vehicle for espionage and intellectual property theft criticisms that have been lent credence by cases such as that of Harvard nanotechnology expert Charles Lieber, who was arrested earlier this year for allegedly lying about his involvement in the programme.

These tensions reflect a deep ambivalence in the rest of the world with regard to Chinas emergence as a scientific superpower that the pandemic has only accentuated by highlighting that neither viruses nor science can be contained within national borders. On the one hand, there is clear recognition that far less would be understood about Covid-19 and the virus that causes it without Chinese research. On the other, there are well-founded concerns about engaging with an authoritarian, one-party regime with a proven disregard for human rights. Muddying an already complex picture are national interests, and a US-China trade war.

The Thousand Talents Plan distils these tensions. Many wealthy countries have lured talent from abroad in fact, it was the UKs Royal Society that coined the term brain drain to describe the exodus of British talent to the US and Canada in the 1950s and 60s. But questions have been raised about how China uses that talent, and the technology that comes with it.

The main concern is how the Chinese Communist party uses technology for the oppression of its people, says James Jin Kang, a cybersecurity expert at Edith Cowan University in Perth, Australia. He adds that anyone buying technology developed in China should worry about data privacy, and that the pandemic has made it easier for China to recruit scientists who are working from home and hence subjected to less institutional oversight than usual.

Chinas approach to ethics has drawn attention in a different way, now that there is a very real prospect of it being the first country to approve a vaccine against Covid-19, and perhaps also to develop effective treatments for the disease. Chinas very good at speed, says Mason. If the game is speed, theyre going to win. There seems little doubt that the party is pushing its scientists to hand it that propaganda coup, causing some to ask what shortcuts are being taken in the process.

Ethical rules do exist in Chinese academia, Ahlers says, though their enforcement is sometimes lax as illustrated by the case of He Jiankui, the scientist who in 2018 announced that he had edited the genes of human babies for the first time (he was punished later, though, with a prison sentence). There is also greater emphasis on the collective good than in western countries, so that testing an experimental Covid-19 vaccine on military personnel which might be considered unacceptable in Europe or the US is more acceptable there.

Yangyang Cheng, a physicist at Cornell University in New York and sometime critic of the Chinese regime, has written about how loyalty to the party overrides ethical considerations in China with troubling implications for research. But she points out that debates about what is ethical with respect to a vaccine have raged in the US, too, and that westerners need to ask themselves what they are really concerned about when they look east. Are they concerned because it is being done unethically, or because it is being done in China? she asks. I think these two things are often conflated.

Cheng has been struck by the sinophobia on display in the west since the beginning of this pandemic, starting with scrutiny of Chinese eating habits, and ridicule of members of the Chinese diaspora preparing for a pandemic long before their fellow citizens of non-Chinese origin who were more likely to regard Covid-19 as an exclusively Chinese problem. Theres not just a residual but a very active sinophobia in the west, agrees Christos Lynteris, a medical anthropologist at the University of St Andrews.

Thats unfortunate, he says, because it can prevent foreign observers from taking a clear-eyed view of how China is changing and what problems it faces itself. For Harry Yi-Jui Wu, a historian of medicine at the University of Hong Kong, these include the increasing ungovernability of the Chinese people including scientists. Before the 1980s, science was a state-sanctioned, collective enterprise. Afterwards, it became more individualistic and commercially oriented. Scientists took more pride in publishing in high-impact journals and in obtaining patents, Wu says. Though there was still political interference in the choice of research subjects, and over the publication process, the science itself the gathering and analysis of data was relatively free. These are paradoxes that are very common in authoritarian or totalitarian regimes, Lynteris says.

The regime has also made adjustments to its strategy, to keep its ultimate goal of global scientific leadership in sight. Earlier this year, for example, it banned bonuses for publications, encouraging researchers to focus on impact instead, and to publish more in Chinese journals. It has its own fears about foreign espionage. A draft data security law unveiled this year could limit the international sharing of data generated in China. Given the sway China already holds scientifically, as Sonia Qingyang Li of the MPIWG writes in a forthcoming paper, the impact of such changes will likely be felt globally.

The increasing ungovernability of Chinese scientists has also been revealed by this pandemic. As science journalist Debora Mackenzie notes in her book Covid-19, a lab in Shanghai that tried to raise the alarm over the new virus was shut down in early January. But Cheng says the censorship can be traced back to local, not central, authorities. The central government is not directing that censorship directly, she says. But it has created this environment of fear and tension in which local politicians are motivated to suppress any bad news.

The social credit system for monitoring trustworthiness, which has been under construction for five years, could be seen as an instrument of the self-discipline that the party has imposed since the hardline Xi Jinping came to power, to help it maintain control. Its not the only one. Wu is planning to leave Hong Kong soon, feeling that its no longer safe to investigate Chinese history critically there. Such a perception is hardly conducive to Chinas attempts to portray itself as an attractive place to do science, and Ahlers says that Thousand Talents has hit a ceiling in terms of recruiting foreign talent. Besides returning Chinese academics, that talent has mainly consisted of retired professors. China is missing out on the intermediate stratum of active, up-and-coming, mid-career scientists, she says.

How will these tensions be resolved? Within 20 years, Kang predicts, the party will be forced to loosen its grip and give Chinese people more freedom including more scientific freedom. Until then, he says, it will continue to behave aggressively, using technology to increase its power, unless western nations cooperate to prevent it.

The pandemic might provide an opportunity to establish the ground rules of a new relationship. Many Chinese people feel pride in the way their government has handled the crisis, especially when they compare it to the responses of governments in supposedly advanced nations. Many of my friends who are professors say we did well, we set an example why didnt the west want to learn? Is it pride? says economist Dabo Guan of Tsinghua University in Beijing and University College London. And prominent Chinese biomedical scientists have expressed dismay and irritation at persistent western hostility. They see this double standard in how we look at China and what we do ourselves, says Ahlers.

We should welcome Chinas growth in science, says Venki Ramakrishnan, Nobel laureate and president of the Royal Society. For him, that means China should be free to recruit overseas, as western nations have for decades. But at the same time, he adds, we should stand up for what we consider our values, which I believe are universal values theyre not the preserve of the west. They are those values that ensure that science and, indeed, humanity flourish.

Read the rest here:

Can we trust Chinese Covid-19 science? - The Guardian

SD County Reports 408 New COVID-19 Cases, Another Death – KPBS

October 12, 2020

Photo by Alexander Nguyen

Above: A coronavirus safety advisory sign at the Plaza de Panama in Balboa Park on Aug. 30, 2020.

San Diego County public health officials have reported 408 new COVID-19 infections and one more death from the illness, raising the county's totals to 50,551 cases and 826 fatalities.

The death of one man was noted Saturday. He was in his mid-40s and had an underlying medical condition.

Of the 9,875 tests reported Saturday, 4% returned positive, bringing the 14-day rolling average percentage of positive cases to 2.9%. The seven-day daily average of tests was 10,281.

Of the total number of cases in the county, 3,681 or 7.3% have required hospitalization and 851 or 1.7% of all cases had to be admitted to an intensive care unit.

Seven new community outbreaks were reported Saturday, one in a faith- based agency, one in a restaurant, one in a grocery setting, two in businesses and two in restaurant/bar settings.

In the past seven days, Oct. 4 through Oct. 10, 45 community outbreaks were confirmed, well above the trigger of seven or more in a week's time. A community setting outbreak is defined as three or more COVID-19 cases in a setting and in people of different households over the past 14 days.

The county remains in the second or red tier of the state's four- tier COVID-19 reopening plan. San Diego's state-calculated, adjusted case rate is 6.5 per 100,000 residents, down from 6.7. The unadjusted case rate is 7.0, down from 7.2.

The testing positivity percentage is 3.5%, the same as last week, and it is in the third or orange tier.

On Saturday, the county allowed private gatherings of up to three households, based on the state's new guidance issued Friday.

The gatherings must take place outdoors. If at someone's home, guests may go inside to use the bathroom.

Participants in a gathering need to stay at least six feet apart from non-household members and wear face coverings. Gatherings should be kept to two hours or less, the new guidelines state.

A health equity metric will now be used to determine how quickly a county may advance through the reopening plan, San Diego Public Health Officer Dr. Wilma Wooten said Wednesday.

A community can only be as well as its unhealthiest quartile, she said, and while counties with a large disparity between the least and most sick members of a community will not be punished for the disparity by sliding back into more restrictive tiers, such a disparity will stop counties from advancing to less-restrictive tiers.

According to the state guidelines, the health equity will measure socially determined health circumstances, such as a community's transportation, housing, access to health care and testing, access to healthy food and parks.

Neighborhoods are grouped and scored by census tracts on the Healthy Places Index, https://healthyplacesindex.org/. Some of the unhealthiest neighborhoods include Logan Heights, Valencia Park, downtown El Cajon and National City. According to county data, the county's health equity testing positivity percentage is 6.2 and is in the red tier.

Wooten said the complicated metric will be explained further on Monday, when the state releases an official "playbook" of how it is calculated and what it means to communities throughout the state as they attempt to reopen.

On Tuesday, the California Department of Public Health will issue its next report on county case rates.

KPBS' daily news podcast covering local politics, education, health, environment, the border and more. New episodes are ready weekday mornings so you can listen on your morning commute.

To view PDF documents, Download Acrobat Reader.

Continued here:

SD County Reports 408 New COVID-19 Cases, Another Death - KPBS

Large Trial Will Test Whether BCG Vaccine Protects Against COVID-19 in Healthcare Staff – Technology Networks

October 12, 2020

A largescale global trial designed to test the theory that the widely-used BCG vaccine could help protect against COVID-19 will soon recruit healthcare staff and care home workers in the UK.

The University of Exeter is leading the UK arm of the trial, called the BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial.

TheBRACE trialis coordinated by theMurdoch Childrens Research Institute (MCRI)in Melbourne, Australia. The trial has received more than $10M from the Bill and Melinda Gates Foundation to allow its global expansion. The Peter Sowerby Foundation has contributed funding to support the Exeter trial site.

The UK joins study centres in Australia, the Netherlands, Spain, and Brazil in the largest trial of its kind. Together, the trial will recruit more than 10,000 healthcare staff. Participants will be given either the BCG vaccine (currently given to more than 100 million babies worldwide each year to protect against tuberculosis (TB)) or a placebo injection. In the UK, routine BCG vaccination was stopped in 2005 because of low rates of TB in the general population.

Professor John Campbell, of the University of Exeter Medical School, is the UK lead on the BRACE study. He said: COVID-19 has killed more than a million people globally, with well over 33 million people acquiring the disease, sometimes in its severest forms. BCG has been shown to boost immunity in a generalised way, which may offer some protection against COVID-19. Were excited to be contributing to the large-scale, international BRACE study where we are seeking to establish whether the BCG vaccine could help protect people who are at risk of COVID-19. If it does, we could save lives by administering or topping up this readily available and cost-effective vaccination.

Previous studies suggest that the Bacillus Calmette-Guerin (BCG) vaccine could reduce susceptibility to a range of infections caused by viruses including those similar to the novel coronavirus causing COVID-19. Examining the mechanism by which this may work is part of the trial being conducted by BRACE researchers.

The BCG vaccine boosts immunity by training the immune system to respond to other subsequent infections with greater intensity.

Researchers hope this improved innate immunity will buy crucial time to develop an effective and safe vaccine against COVID-19.

The BRACE trial is initiallyrecruiting care and healthcare workersin the South West of England, who can attend clinics in Exeter. The trial is targeting these professionals because they work in fields with high exposure to COVID-19. The trial is specifically looking at whether the BCG vaccine reduces coronavirus infection or COVID-19 symptom severity.

Professor Campbell added: People on the COVID-19 front line, including healthcare workers and care home workers, are particularly vulnerable to coronavirus infection. Up until now, care home workers have been overlooked by most research. The BRACE trial provides us with a great opportunity to offer potential help to this important group of individuals who are providing healthcare to some of our most vulnerable citizens in important community settings. Id really encourage care-home staff to join us, to help us find out if the BCG vaccine might provide a safe, widely available and cost-effective way to reduce the risk of COVID-19.

In the UK, the trial will be conducted by theExeter Clinical Trials Unitand supported by the local National Institute for Health Research funded Clinical Research Facility. Lynne Quinn, Operations Director of Exeter CTU, said the trial is initially seeking to recruit 1,000 participants who work in care homes and other community healthcare settings. She said: The first wave of recruitment will take place in and around Exeter, and we have exciting plans to expand to other sites across the UK, so we hope to be expanding our recruitment numbers at a later stage.

Professor Nigel Curtis, global lead of the BRACE trial at MCRI, said: We are delighted that the UK is joining this international trial to help determine if we can repurpose an existing safe vaccine to reduce the impact of COVID-19 in healthcare workers, including those working in care homes who are at particular risk.

Participants will be asked to complete a daily symptom diary via an app, be tested for COVID-19 whenever they have symptoms, complete regular questionnaires and provide blood samples. These samples will allow scientists to understand how blood cells respond differently to exposure to COVID-19 and other viruses, with and without the BCG vaccine.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original post:

Large Trial Will Test Whether BCG Vaccine Protects Against COVID-19 in Healthcare Staff - Technology Networks

Why is Baker so reluctant to disclose vital COVID-19 information? – The Boston Globe

October 12, 2020

Six months later, the pandemic is more or less under control in the state. The governor deserves credit for that. But we cant afford any more blind spots. The public needs to keep a close eye on the trends and hold the state accountable when required.

Thats why its worrisome that the Baker administration has provided only partial access to important COVID infection data in nursing homes and other long-term care facilities, even after the governor signed a law to enhance data reporting.

Such lack of transparency and reluctance to disclose key COVID information is not new. Early on, the state wouldnt release COVID infection data by city and town, making it hard to track geographical hotspots. More opacity could have deadly consequences: obscuring the scope and pattern of the pandemic makes it harder for local government officials, epidemiologists, and the public at-large to react to potential hot spots.

In June, Baker signed a broad data collection law that mandated, among other requirements, more information be disclosed about infections at nursing homes, assisted living centers, and other long-term senior care facilities. But the administration is not in full compliance. For instance, the states Department of Public Health is required to report the daily number of cases and deaths for both staff and residents at these facilities, but it is only reporting cases from each institution in broad ranges, such as 1-10 or >30 when the new statute requires precise numbers. Additionally, DPH is failing to disclose the cumulative number of deaths at specific assisted living institutions.

The Baker administration did warn in June, shortly after the governor signed the data reporting legislation, that full disclosure of deaths at nursing homes would take time. But it has already been four months and the gaps persist. The administration has said, via a spokesperson, that the state has provided more data than many other states.

Separately, but related to the issue of tracking COVID-related information in nursing homes, the Baker administration is either slow-walking or flat-out ignoring key public records requests from the Globe.

In June, reporter Todd Wallack filed a request for email messages sent to or received by Secretary Marylou Sudders about nursing homes that had significant outbreaks, like the Soldiers' Home in Holyoke, where at least 76 people have died. The Executive Office of Health and Human Services agreed to provide approximately 800 emails responsive to Wallacks request at a cost of $450, which the Globe immediately paid. EOHHS kept saying it was working on the request but no records were provided for three months despite multiple follow-ups from Globe lawyers and an order from the states Supervisor of Records Rebecca Murray for the government to comply with the law. It wasnt until the Globe threatened EOHHS with a lawsuit that Wallack finally received 69 emails and was told he would receive the rest by mid-October.

In another request, Globe reporter Hanna Krueger asked EOHHS in early April for emails, texts, and any other communication between former Holyoke Soldiers' Home Superintendent Bennett Walsh and HHS officials during the last two weeks in March. Initially, the Baker administration denied the request citing an exemption due to the ongoing investigation at the facility. The Globe appealed to Murray, who determined that the existence of an investigation did not entitle EOHHS to withhold all of the records in their entirety, and ordered EOHHS to provide further response to the Globe. But Krueger has yet to hear from the Baker administration despite repeated follow-ups asking for a response.

The underlying problem resides with our public records law, of course. Without real teeth to it, the supervisor of records has no ability to enforce records disclosure.

Ultimately, this is about accountability. The states early response to the predictable crisis in the nursing home population was halting, chaotic, and in the end, disastrous, the Spotlight Team wrote. Releasing records could make it less likely that the state will repeat the same deadly mistakes.

Editorials represent the views of the Boston Globe Editorial Board. Follow us on Twitter at @GlobeOpinion.

Read the original here:

Why is Baker so reluctant to disclose vital COVID-19 information? - The Boston Globe

Dont know any COVID-19 patients whove died or been in the hospital? That may explain a lot. – The Philadelphia Inquirer

October 12, 2020

But a more fundamental reason for the uneven support of COVID-19 prevention measures may lie in simple math: Despite more than 200,000 deaths and 400,000 hospitalizations in the United States, an Inquirer analysis suggests that in much of the country, the typical person knows no one in either of those categories. (Surveys, including another one by Pew, have reached similar conclusions.)

Read more from the original source:

Dont know any COVID-19 patients whove died or been in the hospital? That may explain a lot. - The Philadelphia Inquirer

COVID-19 in South Dakota: 617 total new cases; Death toll remains at 286; Active cases at 5,865 – KELOLAND.com

October 12, 2020

PIERRE, S.D. (KELO) Active cases of COVID-19 in South Dakota are nearing 6,000, according to the latest update from the South Dakota Department of Health.

On Sunday, 617 total new coronavirus cases were announced, bringing the states total case count to 28,564, up from Saturday (27,947). Total recovered cases are now at 22,413, up 285 from Saturday (22,128).

Active cases went up to another daily record of 5,865, up from Saturday (5,533).

The death toll from COVID-19 remains at 286.

On Wednesday, the DOH added probable cases to case counts. A probable case includes persons with positive antigen test for SARS-CoV-2, which causes COVID-19. There were 75 probable cases announced with 542 new confirmed cases. Confirmed cases are people with positive RT-PCR tests. There are 28,564 total cases (27,943 confirmed cases and 621 probable cases).

Current hospitalizations is now at 266, down from Saturday (267). Total hospitalizations is now at 1,866, up from Saturday (1,829).

Total persons tested negative is now at 189,547, up from Saturday (188,538).

There were 1,626 new persons tested reported on Sunday, down from Saturday (2,332).

Read more:

COVID-19 in South Dakota: 617 total new cases; Death toll remains at 286; Active cases at 5,865 - KELOLAND.com

UN in Myanmar comes together to protect people from COVID-19 – UN News

October 12, 2020

I was concerned that I might get infected. Everyone was afraid, says 32-year-old World Health Organization (WHO) data collector Myat Mon Yee.

Since March, Ms. Mon Yee, a computer studies graduate from South Dagon Township in Yangon, has been working at the South Okkalapa Hospital in the former capital. The hospital was planned as the Womens and Children's Hospital but has been transformed into a COVID-19 treatment centre.

Not surprisingly, she was initially quite concerned about working with an infectious disease about which very little was known, except that it was killing people and making others very sick: front line health workers throughout the world have been contracting COVID-19 at a higher rate than almost any other group, except perhaps the elderly. Many doctors, nurses and administrative staff have died.

But I thought about other health personnel and charity workers who were willing to work, and even volunteer, and that took some of my fear away, she continues. And when I started work, I found that the facilities were very well taken care of, which allayed my fears.

Myat Mon Yee

Myat Mon Yee collects data on COVID-19 infections at the South Okkalapa Hospital in Yangon.

For a national health emergency plan to be effective, Government and health workers must have highly reliable data,which means staff such Ms. Mon Yee play a crucial role.

Data is the light at the end of the tunnel, says Dr Fabio Caldas de Mesquita, who heads up the WHOs HIV, Viral Hepatitis and TB teams in Myanmar. We need to know how many people are being treated and how many beds are available for new patients; a little about the patients gender, age, and the state of their illness, and of course where they live and who they have been meeting; and we need to know how many tests are being done, and how many test kits remain available.

We need to know what drugs are being used by the patient; what protective equipment is needed for health care staff; and how many staff are working on treatment and response: these may just seem like numbers, but they are key to decision-making during the crisis, says Dr de Mesquita.

UNICEF/Nyan Zay Htet

Airport staff unload cargo of PPE supplied by UNICEF at Yangon International Airport, Myanmar.

In February it quickly became apparent that the Ministry of Health and Sports did not have enough people to undertake this technical role, so WHO hired three people willing to run the risks associated with hospital work, including Ms. Mon Yee.

"You need to be brave to work in infectious diseases, says Dr de Mesquita. Many applicants for jobs in Myanmar refused the work when they discovered they were going to be working on COVID-19 at hospitals. It was the same in 1987 when I began working with HIV and we didnt know exactly how it infected people."

At work, Ms. Mon Yee wears a mask and face shield, carries sanitizer, and frequently washes her hands. She is provided with protective clothing, including a cap and gown, and the facilities are regularly disinfected.

But she also has to take precautions when she returns home, which she shares with her 95 year old grandmother, her 70 year old mother, her sister, and niece. When I get home, I dont talk to anyone. I immediately shower and soak my clothes in soapy water. I spray disinfectant on all my things, and I stay isolated for an hour.

Despite her precautions, Ms. Mon Yee is very aware that there is no cure for COVID-19, and is concerned about a second wave hitting Myanmar.

The recent increases in the infection rates have made me very anxious, she says. I am happy to be able to contribute to the Government and WHOs response, and am grateful for this opportunity, but I worry about other health workers, who are becoming fatigued.

We just hope the patients will recover quickly from COVID: I want the pandemic to be over soon, and for everyone to be safe.

Follow this link:

UN in Myanmar comes together to protect people from COVID-19 - UN News

66 new COVID-19 cases reported in the Northland on Sunday – Duluth News Tribune

October 12, 2020

Health officials tallied 66 new COVID-19 cases across the Northland on Sunday.

Fifty-one more people tested positive for the virus across Northeastern Minnesota as of Oct. 11, according to data from the Minnesota Department of Health.

Of the new cases, 31 were diagnosed in St. Louis County; 13 are in Itasca County; four were recorded in Aitkin County; three were recorded in Carlton County. Cook, Koochiching and Lake counties had no new cases on Sunday.

Statewide, Minnesota added 1,450 newly reported cases, and another 29,755 tests were completed. This puts the state's single-day testing positivity rate at 4.9%.

There were 10 newly reported deaths due to COVID-19 statewide; none were residents of the Northland.

Fifteen more people tested positive for the virus in Northwestern Wisconsin on Sunday. Douglas County recorded six cases, according to the Wisconsin Department of Health Services. Ashland County also had six new cases. Three more residents of Bayfield County tested positive.

Statewide, Wisconsin reported 2,676 more people with COVID-19, and 10,247 more tests have been completed. This sets the state's single-day positivity rate at 26%.

Seven more people have died due to COVID-19-related illness statewide in Wisconsin; none were residents of Northwestern Wisconsin.

Continue reading here:

66 new COVID-19 cases reported in the Northland on Sunday - Duluth News Tribune

Letter urging Covid-19 vaccine trial participation sparks backlash – STAT

October 12, 2020

The presidents of two historically Black universities in New Orleans thought they were doing a public service by enrolling in a Covid-19 vaccine clinical trial back in August, so much so they urged their campus communities to consider doing the same.

I said we should inform our communities because I think theres something about teaching by example, said Reynold Verret, a biochemist who leads Xavier University of Louisiana. Were two Black men who rolled up their sleeves.

So Verret and Walter Kimbrough of Dillard University were stunned by the fierce backlash that followed their joint letter to faculty, staff, students, and alumni. Hundreds of outraged commenters flooded their schools Instagram, Twitter, and Facebook accounts.

advertisement

Our children are not lab rats for drug companies, said one post. I cant believe a HBCU would do this to our people, said another reply. Tuskegee, Tuskegee. Me and mine arent first in line, said another response.

The episode illustrates the challenges historically Black colleges and universities face as they seek to leverage their legacies of trust within African American communities to bolster lagging Black enrollment in Covid-19 vaccine clinical trials. Their recruitment efforts will need to overcome the deep-seated suspicions many Black Americans hold toward medical researchers, pharmaceutical companies, and the government that stem from long-standing racial injustices perpetrated by those institutions.

advertisement

Now, as the four HBCU medical colleges prepare to host Covid-19 vaccine trials on their campuses, theres hope their efforts will have more success.

Weve engendered a level of trust with communities of color that other organizations, quite frankly, just dont have, said James Hildreth, an immunologist and president of Meharry College of Medicine in Nashville. Its imperative for us as HBCUs to rise to this occasion because people need us.

Meharry College plans to begin a trial of a vaccine made by Novavax next week, with Hildreth as its first participant. The goal is to enroll 300 at the site, but Hildreth thinks they can enroll 600 people, mostly African Americans. The other HBCU medical schools, Howard University College of Medicine in Washington D.C., Morehouse School of Medicine in Atlanta, and Charles R. Drew University of Medicine and Science in Los Angeles, are planning to start their trials in the coming weeks.

By engaging with the four Black medical schools, Hildreth said, they will have individuals who look like them, sitting across the table, having these conversations, and we think thats going to make a huge difference.

As the death toll passes 210,000, the Covid-19 pandemic has laid bare inequalities within the U.S. health care system and labor force, with a large portion of Black workers employed in essential jobs that put them at risk of infection. Black Americans are three times as likely as white Americans to contract the disease, five times as likely to end up in the hospital, and twice as likely to die from it, according to the CDC. Had Black Americans died at the same rate as white Americans, some 20,800 Black people would still be alive.

Yet, clinical trials for vaccines are struggling to recruit from their communities. Moderna, one of the drug companies testing a shot, slowed down its trial after failing to enroll enough people of color among its 30,000 participants though as of last week it said one-third of volunteers were from diverse communities. Pfizer and BioNTech reported that 9 percent of their U.S. clinical trial enrollees are Black and 13 percent are Latino, while some 72 percent are white.

Watching all throughout the summer, you kept seeing stories that say there arent enough African Americans in these trials, said Kimbrough. You had people like Tony Fauci saying thats going to be a problem if we create this vaccine and it doesnt work for Black folks.

Though people are all nearly identical genetically, people of color might respond differently than white people to a vaccine, especially for a respiratory disease, due to social differences such as exposure to air pollution that disproportionately affects Black and Brown communities, or higher rates of chronic diseases such as diabetes or sickle cell.

How we live and where we live impacts how medicine affects us, said Kimbrough. I think thats a powerful conversation that we need to be having.

He enrolled in a Phase 3 trial of the Pfizer and BioNTech vaccine after Verret mentioned in a phone call that hed done the same, through New Orleans Ochsner Health System. The study is double-blinded, so neither the participants nor the researchers know whether they received the vaccination or a placebo until the trial is over. (Because the vaccine doesnt contain any live virus, the participant has no risk of developing Covid-19 from the injection.)

In their letter, Kimbrough and Verret addressed the pain caused by the Tuskegee syphilis study in which Black patients were told they would be treated for the disease but werent and how it eroded trust between the Black community and health care providers.

We understand theyre scared, we understand the history, Kimbrough said, but were not just telling them this, were saying, Look, were doing this.

Outrage poured in nonetheless, fueled in part by a ProPublica story published a day before the presidents letter that found Ochsner had sent Black patients infected with coronavirus home to die despite the threat they could spread the disease to other people.

To Tevon Blair, a 2018 Dillard graduate, part of what made the letter unpalatable was the absence of predominantly white local universities such as Loyola and Tulane.

The red flag in this vaccine trial is that it is not a city-wide partnership with other colleges, Blair tweeted.

Myles Bartholomew, 22, a 2020 Xavier graduate who is pursuing his doctoral degree at Brown University in molecular biology, cellular biology and biochemistry, said that from a researchers point of view, he understood the importance of encouraging Black people to take part in clinical trials and said the presidents were acting unselfishly.

And then from a students perspective, theres a lot of panic and trepidation about anything related to Covid right now, Bartholomew said. He said he would not enroll in a clinical trial for a Covid-19 vaccine and he understands why other Black people wouldnt either due to distrust of medical research.

Those horror stories are something that is part of our history as African Americans, so wed be completely naive to ignore the precedents that have been set, he said.

The presidents responded to the social media criticism.

There was some misinformation that was being exaggerated, said Verret. The suggestion that there was money being paid to me or Dr. Kimbrough? No. That there was money paid to Xavier. No. That Xavier was requiring that all students be in the trial. No. He added that any of the standard clinical trial compensation he received participants are paid a nominal sum for their time he would donate to his parish.

The presidents letter may have helped make some headway in aiding recruitment, said Julia Garcia-Diaz, the principal investigator of the clinical trial at Ochsner. After it went out, she received an email from a woman in her late 60s who said she read the presidents note and wanted to sign up.

Not only was she elderly and African American, but she was a female also, said Garcia-Diaz. She ticked all sorts of boxes because women are also underrepresented in clinical trials.

Kimbrough said if he were to rewrite the letter, he would have addressed it to the general public rather than just his and Xaviers campus communities.

Thats a good lesson in terms of messaging, he said.

The HBCU medical schools have been working to make sure they get the messaging right as they address peoples skepticism. Their outreach includes interacting with faith-based organizations and participating in virtual town halls, like one hosted in September by Howard Universitys radio station and The Black Coalition Against Covid-19.

The major concern that people are expressing is the question, Am I being experimented upon? David Carlisle, the president of Drew and an internist, said during the town hall. I can assure individuals that this vaccine when you are taking it to fight Covid-19 is not an experiment that is being directed against the African American community.

He added that anyone considering enrolling should first ask their doctor if they should take this vaccine, why, and is this vaccine safe for them?

At Morehouse, Valerie Montgomery Rice, the president and an obstetrician and gynecologist, is no stranger to recruiting diverse populations into clinical trials. When she helped run a clinical trial for a birth control pill at the University of Kansas in the 1990s, her site was commended for recruiting the highest percentage of minority women in the country. She said she is confident 60% to 70% of the people enrolled in the vaccine trial on her campus will be people of color, because Morehouse has long cared for the community.

The benefit that is with an HBCU medical college is that we deal with these issues everyday with our community. We are more culturally sensitive and more culturally aware, said Montgomery Rice. We have the trust of the community and weve earned that trust.

View original post here:

Letter urging Covid-19 vaccine trial participation sparks backlash - STAT

Page 725«..1020..724725726727..730740..»